The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy

Cancer

Volumn 106, Issue 2, 2006, Pages 284-286

  Zlobec, Inti ^a   Vuong, Te ^b   Compton, Carolyn C ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Apoptosis protease activating factor 1; Preoperative radiotherapy; Rectal carcinoma; Tumor marker

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1;

ARTICLE; BRACHYTHERAPY; CANCER REGRESSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION AND FORECASTING; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RECTUM CARCINOMA; TUMOR BIOPSY;

APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BRACHYTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PREOPERATIVE CARE; PROGNOSIS; PROTEINS; RECTAL NEOPLASMS;

EID: 30744477459     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21600     Document Type: Article

References (17)

1. DeVita VT Jr., Hellman S, Rosenberg SA. Principles of cancer management: chemotherapy. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology, 6th ed, Chapter 17. Philadelphia: Lippincott Williams & Wilkins, 2001:289-306.
2. Watson AJM. Apoptosis and colorectal cancer. Gut. 2004;53:1701-1709.
3. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis. 2004;9:691-704.
4. Hickman ES, Helin K. The regulation of APAF1 expression during development and tumorigenesis. Apoptosis. 2002;7:161-171.
5. Vuong T, Belliveau P, Michel R, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a Phase I/II study. Dis Colon Rectum. 2002;45:1486-1495.
6. Okonkwo A, Musunuri S, Talamonti M, et al. Molecular markers and prediction of response to chemo-radiation in rectal cancer. Oncol Rep. 2001;8:497-500.
7. Gerard J-P, Chapet O, Nemoz C, et al. Improved Sphincter preservation in low rectal cancer with high-dose pre-operative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol. 2004;22:2404-2409.
8. Mustika R, Budiyanto A, Nishigori C, et al. Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res. 2005;18:59-62.
9. Leo C, Richter C, Horn LC, et al. Expression of Apaf-1 in cervical cancer correlates with lymph node metastasis but not with intratumoral hypoxia. Gynecol Oncol. 2005;97:602-606.
10. Ferraro E, Corvaro M, Cecconi F. Physiological and pathological role of Apaf1 and the apoptosome. J Cell Mol Med. 2003;1:21-34.
11. Yoshida H, Kong YY, Yoshida R, et al. Apaf-1 is required for mitochondrial pathways of apoptosis and brain development. Cell. 1998;94:739-750.
12. Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001;61:6660-6664.
13. Furukawa Y, Nishimura N, Furukawa Y, et al. Apaf-1 is a mediator of E2F-1 induced apoptosis. J Biol Chem. 2002;277:39760-39768.
14. Rodel C, Grabenbauer G, Papadopoulos T, et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys. 2002;52:294-303.
15. Szostak M, Kaur P, Amin P, et al. Apoptosis and Bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol. 2001;165:2126-2130.
16. Tannapfel A, Nublein S, Fietkau R, et al. Apoptosis, proliferation, Bax, Bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Biol Oncol Phys. 1998;41:585-591.
17. Kim NK, Park JK, Lee KY, et al. Apoptosis and its correlation with proliferative activity in rectal cancer. J Surg Oncol. 2002;79:236-242.